会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • IN VITRO MUTAGENESIS
    • 体外突变。
    • EP0448609B1
    • 1993-11-18
    • EP90900787.4
    • 1989-11-21
    • DYNAL A.S.
    • HORNES, ErikKORSNES, Lars
    • C12N15/10C12Q1/68
    • C12Q1/6876C12N15/102C12Q1/6834C12Q2563/143
    • The method for in vitro mutagenesis of a nucleic acid to produce single stranded DNA containing one or more base alterations includes the steps of: a) preparing an insoluble support carrying a nucleic acid to be mutagenised; b) adding a DNA oligonucleotide primer, which has the desired base alteration(s) but sufficient homology to hybridise with the appropriate site on the said first nucleic acid and allowing the primer to bind thereto; c) hybridising where necessary a further primer corresponding to the end of the nucleic acid at which synthesis is to start and adding a polymerase or reverse transcriptase, and nucleotides to form a DNA strand having the desired alteration(s) and including a ligase to ligate the said DNA strand to the primer; d) removing the first nucleic acid from the synthesised DNA strand; and e) removing said liquid therefrom. Advantageously the nucleic acid to be mutagenised is attached to the insoluble support by hybridisation to a nucleic acid probe attached to said support which probe is covalently attached to said insoluble support. Preferably, the insoluble support consists of magnetic particles which are monodisperse and/or superparamagnetic.
    • 4. 发明公开
    • METHOD OF SEPARATING HAEMOPOIETIC PROGENITOR CELLS
    • 分离方法用于分离HÄMATOPOEITISCHEN祖细胞。
    • EP0507839A1
    • 1992-10-14
    • EP91902106.0
    • 1990-12-28
    • DYNAL A.S.
    • FUNDERUD, SteinarSMELAND, Erland, Bremerthun
    • C12N5A61K35C07K16C12N15C12P21G01N33C12R1
    • A61K35/28C07K16/3061
    • The invention provides a method of separating haemopoietic progenitor cells (HPC) from within a mixed population of haemopoietic cells, which may contain malignant cells, characterised in that (1) said mixed population is treated with one or more negative selection antibodies reactive with the DP and DQ antigens of the MHC Class II but not with the monomorphic epitope of the DR antigen on the HPC, said negative selection antibody(s) being bound to magnetic particles before or after binding to said cells and the magnetic particles and attached negative selection antibody and cells being removed to leave a negatively selected population of cells including at least HPC, and (2) HPC and any cells associated therewith are treated with a positive selection antibody reactive with an antigen on said HPC, said antibody being bound to magnetic particles before or after binding to cells carrying said antigen, the magnetic particles and attached cells being separated from other cells by magnetic aggregation and the cells of optionally being liberated from the magnetic particles to leave a positively selected population of cells containing said HPC, steps (1) and (2) being effected in either order so that the said positively selected population of cells is the mixed population treated in step (1) or the said negatively selected population of cells are the cells treated in step (2).
    • 7. 发明公开
    • IgG3 ANTIBODIES WITH SHORTENED HINGE REGION AND A COMPLEMENT ACTIVATION TEST
    • 具有缩短铰链区的IgG3抗体和补体激活试验
    • EP0483194A1
    • 1992-05-06
    • EP90910699.0
    • 1990-07-17
    • DYNAL A.S.
    • MICHAELSEN, TerjeSandlie, Inger
    • A61K39C07K16C07K19C12N5C12N15C12P21C12R1
    • C07K16/18C07K16/00C07K16/44
    • L'invention concerne, dans son premier aspect, l'IgG3 (immunoglobuline G3) modifiée contenant des régions humaines constantes, laquelle comporte une région charnière totale plus courte que l'IgG3 humaine. Dans un second aspect, l'invention concerne également un procédé d'analyse d'un anticorps contre un antigène ou haptène spécifique afin de détecter son efficacité dans l'activation du complément chez des espèces animales, consistant à mettre ledit anticorps en contact avec l'antigène ou le haptène immobilisé afin de former un complexe anticorps/antigène ou haptène immobilisés lequel est ensuite mis en contact avec un complèment provenant de l'espèce animale concernée puis à procéder à l'analyse de composant du complément ainsi formé et lié au complexe anticorps/antigène ou anticorps/haptène, de sorte que l'on peut déterminer l'ampleur et la nature de l'activation du complément par l'anticorps dans l'échantillon.
    • 本发明涉及在其第一方面中,IgG3(免疫球蛋白G3)包含改性的人恒定区,其具有一个总的铰链区比人类IgG3短。 在第二方面,本发明还涉及一种方法,用于分析的抗体针对特定抗原或半抗原的检测其在补体活化的动物物种的有效性,包括使所述抗体与所述 抗原或半抗原,以形成抗体/抗原或半抗原固定化,然后将其与补体从相关动物物种接触,然后与这样形成的补体成分分析进行,并且结合到复杂的 抗体/抗原或抗体/半抗原,从而可以确定样品中抗体对补体激活的程度和性质。